Exenatide (Byetta) as a Novel Treatment Option for Type 2 Diabetes Mellitus
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Exenatide is the first drug in the incretin mimetic class and is indicated for treatment of type 2 diabetes mellitus. Although structurally similar to the native glucagon-like peptide, this synthetic form has a much longer duration of action. Randomized trials have shown exenatide to be efficacious in improving glycemic control when combined with either metformin or a sulfonylurea. The dose is initially 5 mcg subcutaneously twice daily and may be titrated to 10 mcg subcutaneously twice daily to achieve better diabetes management. Nausea, vomiting, and diarrhea were the most common adverse events reported with exenatide therapy. Exenatide is not associated with hypoglycemia, which may provide advantages over adding insulin to a sulfonylurea or metformin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Economic Costs of Diabetes in the U.S. in 2002
American Diabetes Association (2003) · Diabetes Care · doi:10.2337/diacare.26.3.917 · Cited by 4,147
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559 · cited 2×
“In combination with metformin alone DeFronzo et al compared exenatide in type 2 diabetic patients being treated with metformin monotherapy in a multicentered, randomized, triple-blinded, placebo-controlled study (6).”
BackgroundBuse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
Kendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177
Research works printed but not linked: 4
- Amylin Pharmaceuticals, Inc., 2005, Byetta [package insert]
- Meneilly GS, 2003, Diabetes Care, 26, 2835, 10.2337/diacare.26.10.2835 · DOI · Paper page
- Drucker DJ, 1998, Diabetes, 47, 159, 10.2337/diab.47.2.159 · DOI · Paper page
- Parkes DG, 2001, Metabolism, 50, 583, 10.1053/meta.2001.22519 · DOI · Paper page
Cited by
The emergence of peptides in the pharmaceutical business: From exploration to exploitation
Uhlig, T., Kyprianou, T., Martinelli, F. G., Oppici, C. A., Heiligers, D., Hills, D., Calvo, X. R., & Verhaert, P. (2014) · EuPA Open Proteomics · doi:10.1016/j.euprot.2014.05.003 · Cited by 456
Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications
Alharbi, S. H. (2024) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188231222367 · Cited by 358
Regulation of Glucose Homeostasis by GLP-1
Nadkarni, P., Chepurny, O. G., & Holz, G. G. (2014) · Progress in Molecular Biology and Translational Science · doi:10.1016/b978-0-12-800101-1.00002-8 · Cited by 287
The Emerging Role of Polyphenols in the Management of Type 2 Diabetes
Wang, Y., Alkhalidy, H., & Liu, D. (2021) · Molecules · doi:10.3390/molecules26030703 · Cited by 88
Thompson, A., Stephens, J. W., Bain, S. C., & Kanamarlapudi, V. (2016) · PLOS ONE · doi:10.1371/journal.pone.0154229 · Cited by 19
Metadata
- Authors
- Bond, A.
- Venue
- Baylor University Medical Center Proceedings
- Publisher
- Informa UK Limited
- Published
- 2006-07
- Volume
- 19
- Issue
- 3
- Pages
- 281-284
- ISSN
- 0899-8280 (ISSN-L)
- 1525-3252
- OpenAlex
- W1650430460
- Cited by
- 87
- References
- 4
- FWCI
- 0.81
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Exenatide (Byetta) as a Novel Treatment Option for Type 2 Diabetes Mellitus. https://app.cochat.ai/papers/10.1080/08998280.2006.11928181
- The paper
- Bond, A. (2006). Exenatide (Byetta) as a Novel Treatment Option for Type 2 Diabetes Mellitus. Baylor University Medical Center Proceedings. https://doi.org/10.1080/08998280.2006.11928181
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.